Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   


COVID Reference, 4th edition, 372 pages

+ the daily Top 10


  Ovarian Neoplasms

  Free Subscription


Articles published in Br J Cancer

Retrieve available abstracts of 88 articles:
HTML format



Single Articles


    June 2020
  1. MARTINS FC, Couturier DL, Paterson A, Karnezis AN, et al
    Clinical and pathological associations of PTEN expression in ovarian cancer: a multicentre study from the Ovarian Tumour Tissue Analysis Consortium.
    Br J Cancer. 2020 Jun 18. pii: 10.1038/s41416-020-0900.
    PubMed     Abstract available


    May 2020
  2. JIANG YX, Siu MK, Wang JJ, Mo XT, et al
    Ascites-derived ALDH+CD44+ tumour cell subsets endow stemness, metastasis and metabolic switch via PDK4-mediated STAT3/AKT/NF-kappaB/IL-8 signalling in ovarian cancer.
    Br J Cancer. 2020 May 11. pii: 10.1038/s41416-020-0865.
    PubMed     Abstract available


  3. FORD CE, Werner B, Hacker NF, Warton K, et al
    The untapped potential of ascites in ovarian cancer research and treatment.
    Br J Cancer. 2020 May 8. pii: 10.1038/s41416-020-0875.
    PubMed     Abstract available


    April 2020
  4. ZHAO Y, He M, Cui L, Gao M, et al
    Chemotherapy exacerbates ovarian cancer cell migration and cancer stem cell-like characteristics through GLI1.
    Br J Cancer. 2020 Apr 3. pii: 10.1038/s41416-020-0825.
    PubMed     Abstract available


    January 2020
  5. HASEGAWA K, Shimada M, Takeuchi S, Fujiwara H, et al
    A phase 2 study of intraperitoneal carboplatin plus intravenous dose-dense paclitaxel in front-line treatment of suboptimal residual ovarian cancer.
    Br J Cancer. 2020 Jan 31. pii: 10.1038/s41416-020-0734.
    PubMed     Abstract available


  6. WHITWELL HJ, Worthington J, Blyuss O, Gentry-Maharaj A, et al
    Improved early detection of ovarian cancer using longitudinal multimarker models.
    Br J Cancer. 2020 Jan 15. pii: 10.1038/s41416-019-0718.
    PubMed     Abstract available


  7. HORIKAWA N, Abiko K, Matsumura N, Baba T, et al
    Anti-VEGF therapy resistance in ovarian cancer is caused by GM-CSF-induced myeloid-derived suppressor cell recruitment.
    Br J Cancer. 2020 Jan 14. pii: 10.1038/s41416-019-0725.
    PubMed     Abstract available


  8. LIU N, Lin X, Huang C
    Activation of the reverse transsulfuration pathway through NRF2/CBS confers erastin-induced ferroptosis resistance.
    Br J Cancer. 2020;122:279-292.
    PubMed     Abstract available


    November 2019
  9. ANNETT S, Moore G, Short A, Marshall A, et al
    FKBPL-based peptide, ALM201, targets angiogenesis and cancer stem cells in ovarian cancer.
    Br J Cancer. 2019 Nov 27. pii: 10.1038/s41416-019-0649.
    PubMed     Abstract available


    October 2019
  10. HAMESTER F, Legler K, Wichert B, Kelle N, et al
    Prognostic relevance of the Golgi mannosidase MAN1A1 in ovarian cancer: impact of N-glycosylation on tumour cell aggregation.
    Br J Cancer. 2019 Oct 29. pii: 10.1038/s41416-019-0607.
    PubMed     Abstract available


    September 2019
  11. ZHAO J, Giri A, Zhu X, Shrubsole MJ, et al
    Calcium: magnesium intake ratio and colorectal carcinogenesis, results from the prostate, lung, colorectal, and ovarian cancer screening trial.
    Br J Cancer. 2019 Sep 23. pii: 10.1038/s41416-019-0579.
    PubMed     Abstract available


  12. COLOMBO N, Zaccarelli E, Baldoni A, Frezzini S, et al
    Multicenter, randomised, open-label, non-comparative phase 2 trial on the efficacy and safety of the combination of bevacizumab and trabectedin with or without carboplatin in women with partially platinum-sensitive recurrent ovarian cancer.
    Br J Cancer. 2019 Sep 20. pii: 10.1038/s41416-019-0584.
    PubMed     Abstract available


    August 2019
  13. TASSI RA, Gambino A, Ardighieri L, Bignotti E, et al
    FXYD5 (Dysadherin) upregulation predicts shorter survival and reveals platinum resistance in high-grade serous ovarian cancer patients.
    Br J Cancer. 2019 Aug 22. pii: 10.1038/s41416-019-0553.
    PubMed     Abstract available


  14. RUSSELL MR, Graham C, D'Amato A, Gentry-Maharaj A, et al
    Diagnosis of epithelial ovarian cancer using a combined protein biomarker panel.
    Br J Cancer. 2019 Aug 7. pii: 10.1038/s41416-019-0544.
    PubMed     Abstract available


  15. SHI T, Jiang R, Pu H, Yang H, et al
    Survival benefits of dose-dense early postoperative intraperitoneal chemotherapy in front-line therapy for advanced ovarian cancer: a randomised controlled study.
    Br J Cancer. 2019 Aug 6. pii: 10.1038/s41416-019-0543.
    PubMed     Abstract available


    July 2019
  16. LEVASSEUR N, Chia S
    Cancer screening and prevention in BRCA mutation carriers: a missed opportunity?
    Br J Cancer. 2019;121:1-2.
    PubMed     Abstract available


  17. BERNDSEN RH, Castrogiovanni C, Weiss A, Rausch M, et al
    Anti-angiogenic effects of crenolanib are mediated by mitotic modulation independently of PDGFR expression.
    Br J Cancer. 2019;121:139-149.
    PubMed     Abstract available


    June 2019
  18. QIAN F, Rookus MA, Leslie G, Risch HA, et al
    Mendelian randomisation study of height and body mass index as modifiers of ovarian cancer risk in 22,588 BRCA1 and BRCA2 mutation carriers.
    Br J Cancer. 2019 Jun 19. pii: 10.1038/s41416-019-0492.
    PubMed     Abstract available


  19. PLUMMER C, Michael A, Shaikh G, Stewart M, et al
    Expert recommendations on the management of hypertension in patients with ovarian and cervical cancer receiving bevacizumab in the UK.
    Br J Cancer. 2019 Jun 11. pii: 10.1038/s41416-019-0481.
    PubMed     Abstract available


    March 2019
  20. FORTNER RT, Terry KL, Bender N, Brenner N, et al
    Sexually transmitted infections and risk of epithelial ovarian cancer: results from the Nurses' Health Studies.
    Br J Cancer. 2019 Mar 21. pii: 10.1038/s41416-019-0422.
    PubMed     Abstract available


  21. WESTERGAARD MCW, Andersen R, Chong C, Kjeldsen JW, et al
    Correction: Tumour-reactive T cell subsets in the microenvironment of ovarian cancer.
    Br J Cancer. 2019 Mar 19. pii: 10.1038/s41416-019-0425.
    PubMed     Abstract available


    February 2019
  22. WESTERGAARD MCW, Andersen R, Chong C, Kjeldsen JW, et al
    Tumour-reactive T cell subsets in the microenvironment of ovarian cancer.
    Br J Cancer. 2019 Feb 5. pii: 10.1038/s41416-019-0384.
    PubMed     Abstract available


    January 2019
  23. LEE CK, Scott C, Lindeman GJ, Hamilton A, et al
    Phase 1 trial of olaparib and oral cyclophosphamide in BRCA breast cancer, recurrent BRCA ovarian cancer, non-BRCA triple-negative breast cancer, and non-BRCA ovarian cancer.
    Br J Cancer. 2019 Jan 17. pii: 10.1038/s41416-018-0349.
    PubMed     Abstract available


  24. MULATI K, Hamanishi J, Matsumura N, Chamoto K, et al
    VISTA expressed in tumour cells regulates T cell function.
    Br J Cancer. 2019;120:115-127.
    PubMed     Abstract available


    December 2018
  25. SINGEL KL, Grzankowski KS, Khan ANMNH, Grimm MJ, et al
    Mitochondrial DNA in the tumour microenvironment activates neutrophils and is associated with worse outcomes in patients with advanced epithelial ovarian cancer.
    Br J Cancer. 2018 Dec 6. pii: 10.1038/s41416-018-0339.
    PubMed     Abstract available


    October 2018
  26. FRIEDLANDER M, Matulonis U, Gourley C, du Bois A, et al
    Long-term efficacy, tolerability and overall survival in patients with platinum-sensitive, recurrent high-grade serous ovarian cancer treated with maintenance olaparib capsules following response to chemotherapy.
    Br J Cancer. 2018 Oct 24. pii: 10.1038/s41416-018-0271.
    PubMed     Abstract available


  27. HODGSON DR, Dougherty BA, Lai Z, Fielding A, et al
    Candidate biomarkers of PARP inhibitor sensitivity in ovarian cancer beyond the BRCA genes.
    Br J Cancer. 2018 Oct 24. pii: 10.1038/s41416-018-0274.
    PubMed     Abstract available


  28. PATEL JN, Braicu I, Timms KM, Solimeno C, et al
    Characterisation of homologous recombination deficiency in paired primary and recurrent high-grade serous ovarian cancer.
    Br J Cancer. 2018 Oct 15. pii: 10.1038/s41416-018-0268.
    PubMed     Abstract available


  29. NIEMI RJ, Braicu EI, Kulbe H, Koistinen KM, et al
    Ovarian tumours of different histologic type and clinical stage induce similar changes in lipid metabolism.
    Br J Cancer. 2018 Oct 8. pii: 10.1038/s41416-018-0270.
    PubMed     Abstract available


  30. WANG P, Magdolen V, Seidl C, Dorn J, et al
    Kallikrein-related peptidases 4, 5, 6 and 7 regulate tumour-associated factors in serous ovarian cancer.
    Br J Cancer. 2018 Oct 5. pii: 10.1038/s41416-018-0260.
    PubMed     Abstract available


  31. WILLIAMS LA, Mills L, Hooten AJ, Langer E, et al
    Differences in DNA methylation profiles by histologic subtype of paediatric germ cell tumours: a report from the Children's Oncology Group.
    Br J Cancer. 2018 Oct 5. pii: 10.1038/s41416-018-0277.
    PubMed     Abstract available


    August 2018
  32. TSIBULAK I, Wieser V, Degasper C, Shivalingaiah G, et al
    BRCA1 and BRCA2 mRNA-expression prove to be of clinical impact in ovarian cancer.
    Br J Cancer. 2018 Aug 15. pii: 10.1038/s41416-018-0217.
    PubMed     Abstract available


    July 2018
  33. CARTER JH, Deddens JA, Mueller G, Lewis TG, et al
    Transcription factors WT1 and p53 combined: a prognostic biomarker in ovarian cancer.
    Br J Cancer. 2018 Jul 30. pii: 10.1038/s41416-018-0191.
    PubMed     Abstract available


  34. GHAFFARI A, Peterson N, Khalaj K, Vitkin N, et al
    STING agonist therapy in combination with PD-1 immune checkpoint blockade enhances response to carboplatin chemotherapy in high-grade serous ovarian cancer.
    Br J Cancer. 2018 Jul 26. pii: 10.1038/s41416-018-0188.
    PubMed     Abstract available


  35. HILLIARD C
    Comment on 'Dairy, calcium, vitamin D, and ovarian cancer risk in African-American women'.
    Br J Cancer. 2018 Jul 2. pii: 10.1038/s41416-018-0166.
    PubMed    


  36. QIN B, Peres LC, Schildkraut JM, Bandera EV, et al
    Reply to 'Comment on 'Dairy, calcium, vitamin D and ovarian cancer risk in African-American women''.
    Br J Cancer. 2018 Jul 2. pii: 10.1038/s41416-018-0163.
    PubMed    


    June 2018
  37. RUSCITO I, Cacsire Castillo-Tong D, Vergote I, Ignat I, et al
    Characterisation of tumour microvessel density during progression of high-grade serous ovarian cancer: clinico-pathological impact (an OCTIPS Consortium study).
    Br J Cancer. 2018 Jun 29. pii: 10.1038/s41416-018-0157.
    PubMed     Abstract available


  38. SHI T, Jiang R, Yu J, Yang H, et al
    Addition of intraperitoneal cisplatin and etoposide to first-line chemotherapy for advanced ovarian cancer: a randomised, phase 2 trial.
    Br J Cancer. 2018 Jun 14. pii: 10.1038/s41416-018-0036.
    PubMed     Abstract available


  39. VIALATTE DE PEMILLE C, Berzero G, Small M, Psimaras D, et al
    Transcriptomic immune profiling of ovarian cancers in paraneoplastic cerebellar degeneration associated with anti-Yo antibodies.
    Br J Cancer. 2018 Jun 14. pii: 10.1038/s41416-018-0125.
    PubMed     Abstract available


  40. ZHENG R, Du M, Zhang B, Xin J, et al
    Body mass index (BMI) trajectories and risk of colorectal cancer in the PLCO cohort.
    Br J Cancer. 2018 Jun 6. pii: 10.1038/s41416-018-0121.
    PubMed     Abstract available


  41. TUNG NM, Garber JE
    BRCA1/2 testing: therapeutic implications for breast cancer management.
    Br J Cancer. 2018 Jun 5. pii: 10.1038/s41416-018-0127.
    PubMed     Abstract available


    March 2018
  42. DIXON-SUEN SC, Nagle CM, Thrift AP, Pharoah PDP, et al
    Adult height is associated with increased risk of ovarian cancer: a Mendelian randomisation study.
    Br J Cancer. 2018 Mar 20. pii: 10.1038/s41416-018-0011.
    PubMed     Abstract available


  43. DI GIROLAMO C, Walters S, Gildea C, Benitez Majano S, et al
    Which patients are not included in the English Cancer Waiting Times monitoring dataset, 2009-2013? Implications for use of the data in research.
    Br J Cancer. 2018;118:733-737.
    PubMed     Abstract available


    February 2018
  44. YUZHALIN AE, Urbonas T, Silva MA, Muschel RJ, et al
    A core matrisome gene signature predicts cancer outcome.
    Br J Cancer. 2018;118:435-440.
    PubMed     Abstract available


    January 2018
  45. VERDOODT F, Kjaer SK, Dehlendorff C, Friis S, et al
    Aspirin use and ovarian cancer mortality in a Danish nationwide cohort study.
    Br J Cancer. 2018 Jan 9. pii: bjc2017449. doi: 10.1038/bjc.2017.
    PubMed     Abstract available


    December 2017
  46. PLAYDON MC, Coburn SB, Moore SC, Brinton LA, et al
    Alcohol and oestrogen metabolites in postmenopausal women in the Women's Health Initiative Observational Study.
    Br J Cancer. 2017 Dec 12. pii: bjc2017419. doi: 10.1038/bjc.2017.
    PubMed     Abstract available


    November 2017
  47. KAWAKITA D, Lee YA, Gren LH, Buys SS, et al
    The impact of folate intake on the risk of head and neck cancer in the prostate, lung, colorectal, and ovarian cancer screening trial (PLCO) cohort.
    Br J Cancer. 2017 Nov 21. doi: 10.1038/bjc.2017.
    PubMed     Abstract available


    October 2017
  48. POYNTER JN, Richardson M, Roesler M, Krailo M, et al
    Family history of cancer in children and adolescents with germ cell tumours: a report from the Children's Oncology Group.
    Br J Cancer. 2017 Oct 24. doi: 10.1038/bjc.2017.
    PubMed     Abstract available


    September 2017
  49. GAYARRE J, Martin-Gimeno P, Osorio A, Paumard B, et al
    Characterisation of the novel deleterious RAD51C p.Arg312Trp variant and prioritisation criteria for functional analysis of RAD51C missense changes.
    Br J Cancer. 2017;117:1048-1062.
    PubMed     Abstract available


  50. WANG X, Zhu Q, Lin Y, Wu L, et al
    Crosstalk between TEMs and endothelial cells modulates angiogenesis and metastasis via IGF1-IGF1R signalling in epithelial ovarian cancer.
    Br J Cancer. 2017 Sep 12. doi: 10.1038/bjc.2017.
    PubMed     Abstract available


    August 2017
  51. CALLAHAN CL, Schwartz K, Ruterbusch JJ, Shuch B, et al
    Leukocyte telomere length and renal cell carcinoma survival in two studies.
    Br J Cancer. 2017;117:752-755.
    PubMed     Abstract available


  52. BELGIOVINE C, Bello E, Liguori M, Craparotta I, et al
    Lurbinectedin reduces tumour-associated macrophages and the inflammatory tumour microenvironment in preclinical models.
    Br J Cancer. 2017;117:628-638.
    PubMed     Abstract available


  53. MINLIKEEVA AN, Freudenheim JL, Cannioto RA, Eng KH, et al
    History of thyroid disease and survival of ovarian cancer patients: results from the Ovarian Cancer Association Consortium, a brief report.
    Br J Cancer. 2017 Aug 17. doi: 10.1038/bjc.2017.
    PubMed     Abstract available


  54. CHEN Y, Wang DD, Wu YP, Su D, et al
    MDM2 promotes epithelial-mesenchymal transition and metastasis of ovarian cancer SKOV3 cells.
    Br J Cancer. 2017 Aug 17. doi: 10.1038/bjc.2017.
    PubMed     Abstract available


  55. SHARMA R, Huang X, Brekken RA, Schroit AJ, et al
    Detection of phosphatidylserine-positive exosomes for the diagnosis of early-stage malignancies.
    Br J Cancer. 2017;117:545-552.
    PubMed     Abstract available


  56. TABUNG FK, Huang T, Giovannucci EL, Smith-Warner SA, et al
    The inflammatory potential of diet and ovarian cancer risk: results from two prospective cohort studies.
    Br J Cancer. 2017 Aug 3. doi: 10.1038/bjc.2017.
    PubMed     Abstract available


    July 2017
  57. MENON U, McGuire AJ, Raikou M, Ryan A, et al
    The cost-effectiveness of screening for ovarian cancer: results from the UK Collaborative Trial of Ovarian Cancer Screening (UKCTOCS).
    Br J Cancer. 2017 Jul 25. doi: 10.1038/bjc.2017.
    PubMed     Abstract available


  58. ITAMOCHI H, Oishi T, Oumi N, Takeuchi S, et al
    Whole-genome sequencing revealed novel prognostic biomarkers and promising targets for therapy of ovarian clear cell carcinoma.
    Br J Cancer. 2017 Jul 20. doi: 10.1038/bjc.2017.
    PubMed     Abstract available


    June 2017
  59. RUSSELL MR, Graham C, D'Amato A, Gentry-Maharaj A, et al
    A combined biomarker panel shows improved sensitivity for the early detection of ovarian cancer allowing the identification of the most aggressive type II tumours.
    Br J Cancer. 2017 Jun 29. doi: 10.1038/bjc.2017.
    PubMed     Abstract available


  60. SERENI MI, Baldelli E, Gambara G, Ravaggi A, et al
    Kinase-driven metabolic signalling as a predictor of response to carboplatin-paclitaxel adjuvant treatment in advanced ovarian cancers.
    Br J Cancer. 2017 Jun 29. doi: 10.1038/bjc.2017.
    PubMed     Abstract available


  61. WEISS GJ, Waypa J, Blaydorn L, Coats J, et al
    A phase Ib study of pembrolizumab plus chemotherapy in patients with advanced cancer (PembroPlus).
    Br J Cancer. 2017;117:33-40.
    PubMed     Abstract available


  62. BANDERA EV, Lee VS, Qin B, Rodriguez-Rodriguez L, et al
    Impact of body mass index on ovarian cancer survival varies by stage.
    Br J Cancer. 2017 Jun 6. doi: 10.1038/bjc.2017.
    PubMed     Abstract available


  63. BAHLEDA R, Grilley-Olson JE, Govindan R, Barlesi F, et al
    Phase I dose-escalation studies of roniciclib, a pan-cyclin-dependent kinase inhibitor, in advanced malignancies.
    Br J Cancer. 2017;116:1505-1512.
    PubMed     Abstract available


    May 2017
  64. PLAYDON MC, Nagle CM, Ibiebele TI, Ferrucci LM, et al
    Pre-diagnosis diet and survival after a diagnosis of ovarian cancer.
    Br J Cancer. 2017 May 2. doi: 10.1038/bjc.2017.
    PubMed     Abstract available


    April 2017
  65. DURAN GE, Wang YC, Moisan F, Francisco EB, et al
    Decreased levels of baseline and drug-induced tubulin polymerisation are hallmarks of resistance to taxanes in ovarian cancer cells and are associated with epithelial-to-mesenchymal transition.
    Br J Cancer. 2017 Apr 11. doi: 10.1038/bjc.2017.
    PubMed     Abstract available


    March 2017
  66. GORANOVA T, Ennis D, Piskorz AM, Macintyre G, et al
    Safety and utility of image-guided research biopsies in relapsed high-grade serous ovarian carcinoma-experience of the BriTROC consortium.
    Br J Cancer. 2017 Mar 30. doi: 10.1038/bjc.2017.
    PubMed     Abstract available


  67. DIXON SC, Nagle CM, Wentzensen N, Trabert B, et al
    Use of common analgesic medications and ovarian cancer survival: results from a pooled analysis in the Ovarian Cancer Association Consortium.
    Br J Cancer. 2017 Mar 28. doi: 10.1038/bjc.2017.
    PubMed     Abstract available


  68. PHELPS DL, Borley JV, Flower KJ, Dina R, et al
    Methylation of MYLK3 gene promoter region: a biomarker to stratify surgical care in ovarian cancer in a multicentre study.
    Br J Cancer. 2017 Mar 28. doi: 10.1038/bjc.2017.
    PubMed     Abstract available


  69. BEGG CB, Rice MS, Zabor EC, Tworoger SS, et al
    Examining the common aetiology of serous ovarian cancers and basal-like breast cancers using double primaries.
    Br J Cancer. 2017 Mar 23. doi: 10.1038/bjc.2017.
    PubMed     Abstract available


  70. FALLOWFIELD L, Solis-Trapala I, Menon U, Langridge C, et al
    The effect of ovarian cancer screening on sexual activity and functioning: results from the UK collaborative trial of ovarian cancer screening RCT.
    Br J Cancer. 2017 Mar 21. doi: 10.1038/bjc.2017.
    PubMed     Abstract available


  71. SHATHASIVAM P, Kollara A, Spybey T, Park S, et al
    VEPH1 expression decreases vascularisation in ovarian cancer xenografts and inhibits VEGFA and IL8 expression through inhibition of AKT activation.
    Br J Cancer. 2017 Mar 16. doi: 10.1038/bjc.2017.
    PubMed     Abstract available


    February 2017
  72. KIM SJ, Rosen B, Fan I, Ivanova A, et al
    Epidemiologic factors that predict long-term survival following a diagnosis of epithelial ovarian cancer.
    Br J Cancer. 2017 Feb 16. doi: 10.1038/bjc.2017.
    PubMed     Abstract available


    January 2017
  73. LINDEMANN K, Gibbs E, Avall-Lundqvist E, dePont Christensen R, et al
    Chemotherapy vs tamoxifen in platinum-resistant ovarian cancer: a phase III, randomised, multicentre trial (Ovaresist).
    Br J Cancer. 2017 Jan 24. doi: 10.1038/bjc.2016.
    PubMed     Abstract available


  74. KAR SP, Adler E, Tyrer J, Hazelett D, et al
    Enrichment of putative PAX8 target genes at serous epithelial ovarian cancer susceptibility loci.
    Br J Cancer. 2017 Jan 19. doi: 10.1038/bjc.2016.
    PubMed     Abstract available


  75. HEUDEL PE, Fabbro M, Roemer-Becuwe C, Kaminsky MC, et al
    Phase II study of the PI3K inhibitor BKM120 in patients with advanced or recurrent endometrial carcinoma: a stratified type I-type II study from the GINECO group.
    Br J Cancer. 2017 Jan 10. doi: 10.1038/bjc.2016.
    PubMed     Abstract available


    December 2016
  76. KOMMOSS S, Kommoss F, Diebold J, Lax S, et al
    Better resource utilisation and quality of care for ovarian cancer patients using internet-based pathology review.
    Br J Cancer. 2016 Dec 22. doi: 10.1038/bjc.2016.
    PubMed     Abstract available


  77. COOK LS, Pestak CR, Leung AC, Steed H, et al
    Combined oral contraceptive use before the first birth and epithelial ovarian cancer risk.
    Br J Cancer. 2016 Dec 13. doi: 10.1038/bjc.2016.
    PubMed     Abstract available


  78. LICAJ I, Jacobsen BK, Selmer RM, Maskarinec G, et al
    Smoking and risk of ovarian cancer by histological subtypes: an analysis among 300 000 Norwegian women.
    Br J Cancer. 2016 Dec 13. doi: 10.1038/bjc.2016.
    PubMed     Abstract available


    November 2016
  79. LI X, Chen W, Zeng W, Wan C, et al
    microRNA-137 promotes apoptosis in ovarian cancer cells via the regulation of XIAP.
    Br J Cancer. 2016 Nov 22. doi: 10.1038/bjc.2016.
    PubMed     Abstract available


  80. LEDERMANN JA, Harter P, Gourley C, Friedlander M, et al
    Quality of life during olaparib maintenance therapy in platinum-sensitive relapsed serous ovarian cancer.
    Br J Cancer. 2016 Nov 8. doi: 10.1038/bjc.2016.
    PubMed     Abstract available


    October 2016
  81. ZAAIJER LH, van Doorn HC, Mourits MJ, van Beurden M, et al
    Outcome of ovarian cancer after breast cancer in BRCA1 and BRCA2 mutation carriers.
    Br J Cancer. 2016 Oct 18. doi: 10.1038/bjc.2016.
    PubMed     Abstract available


  82. KONECNY GE, Kristeleit RS
    PARP inhibitors for BRCA1/2-mutated and sporadic ovarian cancer: current practice and future directions.
    Br J Cancer. 2016 Oct 13. doi: 10.1038/bjc.2016.
    PubMed     Abstract available


  83. SHAFRIR AL, Babic A, Tamimi RM, Rosner BA, et al
    Reproductive and hormonal factors in relation to survival and platinum resistance among ovarian cancer cases.
    Br J Cancer. 2016 Oct 4. doi: 10.1038/bjc.2016.
    PubMed     Abstract available


    September 2016
  84. HUANG J, Mondul AM, Weinstein SJ, Koutros S, et al
    Serum metabolomic profiling of prostate cancer risk in the prostate, lung, colorectal, and ovarian cancer screening trial.
    Br J Cancer. 2016 Sep 27. doi: 10.1038/bjc.2016.
    PubMed     Abstract available


  85. DONAT-VARGAS C, Akesson A, Berglund M, Glynn A, et al
    Dietary exposure to polychlorinated biphenyls and risk of breast, endometrial and ovarian cancer in a prospective cohort.
    Br J Cancer. 2016 Sep 15. doi: 10.1038/bjc.2016.
    PubMed     Abstract available


  86. QIN B, Moorman PG, Alberg AJ, Barnholtz-Sloan JS, et al
    Dairy, calcium, vitamin D and ovarian cancer risk in African-American women.
    Br J Cancer. 2016 Sep 15. doi: 10.1038/bjc.2016.
    PubMed     Abstract available


  87. KOMMOSS S, Gilks CB, du Bois A, Kommoss F, et al
    Ovarian carcinoma diagnosis: the clinical impact of 15 years of change.
    Br J Cancer. 2016 Sep 15. doi: 10.1038/bjc.2016.
    PubMed     Abstract available


    August 2016
  88. VAN DER PUTTEN LJ, Visser NC, van de Vijver K, Santacana M, et al
    L1CAM expression in endometrial carcinomas: an ENITEC collaboration study.
    Br J Cancer. 2016 Aug 9. doi: 10.1038/bjc.2016.
    PubMed     Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Ovarian Neoplasms is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: